Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026GlobeNewsWire • 05/28/26
New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026GlobeNewsWire • 05/27/26
Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026GlobeNewsWire • 05/13/26
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026GlobeNewsWire • 05/06/26
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of SecuritiesGlobeNewsWire • 04/27/26
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of SecuritiesGlobeNewsWire • 04/23/26
ALT Stock and the 2026 MASH Race: Dual Agonists vs. New MechanismsZacks Investment Research • 03/26/26
Altimmune, Inc. (ALT) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/12/26